ARTICLE | Clinical News
CTIC starts Trisenox myeloma trials
January 31, 2001 8:00 AM UTC
Cell Therapeutics (CTIC) began U.S. Phase II testing of its Trisenox arsenic trioxide chemical compound in up to 55 patients with multiple myeloma who have relapsed following up to 3 prior treatments....